Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
about
Pharmacogenomics: personalizing pediatric heart transplantationPopulation pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.Bayesian model selection validates a biokinetic model for zirconium processing in humans.Role of pharmacogenomics in dialysis and transplantationPaediatric models in motion: requirements for model-based decision support at the bedside.Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation.Dosing equation for tacrolimus using genetic variants and clinical factorsClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients.Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipientsMultidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipientsA Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.Factors affecting the development of adverse drug reactions (Review article)Population pharmacokinetic analysis of axitinib in healthy volunteers.Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration.Outcomes in pediatric solid-organ transplantation.Developmental pharmacogenomics.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.The role of genetics in drug dosingOntogeny of oral drug absorption processes in children.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Pediatric perspective on pharmacogenomics.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Dosage individualization in children: integration of pharmacometrics in clinical practice.Choosing the right dose of tacrolimus.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?Pharmacogenetics of posttransplant diabetes mellitus.Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients.The impact of a change in tacrolimus monitoring immunoassay techniques on clinical decision making.
P2860
Q28081200-8C6E2B2F-804A-46D6-B404-E4D971B7D665Q33888004-F9365A42-EAA6-4CEA-ABB9-663DF5B4B1A8Q34366020-45A8FF9E-4514-49D3-BEB7-5AEFB0DAA167Q34454797-1BE7C4FF-30E2-4133-B409-8B302F5C8CCAQ34953686-B6DBE0D0-9FAB-4CEF-BD15-F4CF0EFAFC5FQ35016679-AB8368FF-D345-48AF-BDD9-8F4BBDCE84BFQ35544537-4BE734AD-C8A6-4D36-8D09-99DF220E0004Q35629782-37A4DBD3-C50F-43CA-8AC4-E5A7F7C6D79AQ35782898-2D013F43-638B-4115-AD9E-156ECEF78A38Q35916672-1D789145-C035-4C86-A30E-7CBA71D10D29Q36125433-D0C9B4C9-F26A-42CC-AC44-3A384F37709DQ36465101-43DC37D4-F572-4E8D-A0ED-94AB98030273Q36806652-976FA895-11A4-434D-BD24-D025D9CA51B6Q37126092-EA9BA2FE-DBC9-42D0-9057-2374DB6B45F4Q37207789-194C0722-2705-4B86-9AFA-308EA33EB981Q37620393-0EA0EEEF-9D08-4701-8177-C2596A069C43Q37631543-10905EBA-E55A-45BF-8433-6DE20B4D5F64Q37635202-6184F635-27FE-46E1-9AEC-C06391113905Q37728538-631CDAF2-7FFF-406E-9A8B-22FD2B2344BFQ37839213-BC00E995-8F3D-4B0C-BACD-FAD880ED4FD5Q37841723-379A5CC5-9915-4286-BB24-7304FEA0FEB5Q37892531-9C2F497A-0E4D-4D07-8037-EF927E7CBAF3Q37987439-2AE6F64E-5E1F-45C0-B9AE-53496261CC42Q38017723-784A8AE1-FA1E-441B-A861-2E45AD9C8CDCQ38063426-F694F5ED-43FF-46F5-83E6-C94FE118FD40Q38086777-99686814-EDEC-4EDE-B8A4-04CC128A0E91Q38162869-18E9FFE2-7565-4E01-B986-86D46269E2B6Q38163945-057D0BFB-673F-4480-8302-C69B6EAC440AQ38240055-FE59DE50-C032-4249-B529-025B525ADE8CQ38270520-3B425A6D-FEE1-4D86-84A0-76BAF8199C77Q38417581-E36D217E-65CD-4F3A-97EA-87CE418B73AAQ38501680-70D65782-7123-47EF-8F5F-276ED1ACBB3BQ38534443-184AEA9F-306E-4810-B496-68A57033E18DQ38612229-2337F126-D479-4815-A53C-2CA2EAC08B18Q38691788-2B30254E-115F-4552-8BF6-A8BAA5651CFEQ38787174-16B6BEC0-86B4-4BF0-89DE-BDC77E8A5D78Q38809767-219CE5A4-9A67-4C61-988A-83126FB5AD46Q39204562-20F87E9A-DE44-4346-951A-F936B9D01AAEQ39816513-593A1C91-279C-4682-B29D-7B2388C951B2Q42755088-E7195CDE-D611-45D2-8257-E83F3816F3F8
P2860
Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Population pharmacokinetics an ...... kidney transplant recipients.
@en
Population pharmacokinetics an ...... kidney transplant recipients.
@nl
type
label
Population pharmacokinetics an ...... kidney transplant recipients.
@en
Population pharmacokinetics an ...... kidney transplant recipients.
@nl
prefLabel
Population pharmacokinetics an ...... kidney transplant recipients.
@en
Population pharmacokinetics an ...... kidney transplant recipients.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics an ...... c kidney transplant recipients
@en
P2093
K Brochard
M Fakhoury
P2860
P304
P356
10.1038/CLPT.2009.210
P407
P577
2009-10-28T00:00:00Z